Latest Breaking News On - ஜெனிபர் மக்நீல் - Page 1 : comparemela.com

PerkinElmer, Inc.: PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology

Jennifer mcneilAlan fletcherGoethe university in frankfurtLife sciences at perkinelmerGerman federal ministry of educationFraunhofer institute for translational medicineTechnical university of darmstadtPerkinelmer incGoethe university frankfurtTargeting chimerasGoethe universityTechnical universityFraunhofer instituteTranslational medicineLife sciencesGerman federal ministry